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INTRODUCTION
Immunoglobulin A nephropathy (IgAN), also known as
Berger’s disease, is the most common global type of glom-
erulonephritis; however, the geographical distribution of the
disease varies (Rodrigues et al., 2017; Schena and Nistor,
2018). The disease can manifest at any age, but it is more
common in young adults, especially in the second and third
decade of life (Cheung and Barratt, 2020). Annual inci-
dence of IgAN is around 2.5/100 000 people (McGrogan et
al., 2011). Imbalance of the disease in the male and female
population can be found, and the male-to-female ratio is
2–6 : 1 (Roberts, 2019). Among glomerular diseases, IgAN
can lead to end-stage kidney disease (ESRD) (Rodrigues et
al., 2017). There is still no effective treatment for this dis-
ease, and the main goal of IgAN treatment is blood-pressure
and proteinuria control, along with the maintenance of re-
sidual kidney function (Lai et al., 2016).
IgAN progression is uncertain, and there are no clearly de-
fined criteria for disease outcome. IgAN prognosis has been
based on clinical and histological parameters until now.
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The aim of the study was to determine kidney survival and validate the novel international immu-
noglobulin A nephropathy (IgAN) prediction tool (PT) in the Latvian population. Adults with mor-
phologically confirmed IgAN were included. Kidney survival was analysed with the Kaplan–Meier
method. PT-assigned risk was compared with calculated risk by the Cox regression model. The
Kaplan–Meier analysis included 95 patients. The five-year kidney survival Q3 was 24 months.
Women had longer median kidney-survival time (> 60 months) than men (58 months). Median
kidney survival in participants with MEST T0 was longer than 60 months; T1 and T2 were 40 and
18 months, respectively. Median kidney survival in participants with diastolic blood pressure
(DBP) < 99 mmHg was longer than 60 months, whereas in patients with DBP 100–109 and 110
mmHg, it was 40 and 24 months, respectively. Cox regression analysis included 68 patients. A
moderate degree of correlation was found between predicted and observed five-year risk (p =
0.001). Gender, tubular atrophy/interstitial fibrosis, DBP are significant factors affecting kidney
survival. Since there was statistically significant correlation and reliability between PT and fol-
low-up analysis data, we conclude that PT could be applied for use in the Latvian population.
Key words: immunoglobulin A nephropathy, novel IgAN prediction tool, kidney survival risk fac-
tors, end-stage kidney disease.
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Clinical parameters that are associated with poor prognosis
are hypertension, 24-hour proteinuria, and decreased glom-
erular filtration rate (GFR) at the time of the biopsy; patient
race, gender, and comorbidities can also affect disease out-
come (Rodrigues et al., 2017). IgAN is heterogeneous in
clinical presentation in different populations, displaying
surprising geographic variation. For example, IgAN is the
most common cause of kidney failure in Asia but it is very
rare among individuals of African ancestry (Kiryluk et al.,
2012). Histological parameters that determine IgAN prog-
nosis are included in the Oxford Classification of Immuno-
globulin A nephropathy (MEST score): mesangial hypercel-
lularity (M); endocapillary hypercellularity (E); segmental
glomerulosclerosis (S); and tubular atrophy/interstitial fi-
brosis (T). This classification was published in 2009 and is
an international system for evaluating pathological features
on kidney biopsy. Since it was unknown whether kidney-
pathology lesions in IgAN are correlated with kidney out-
come, VALIGA (a validation study of the Oxford classifica-
tion for IgA nephropathy) started in 2010. The study identi-
fied four variables (M, E, S, and T) that are strongly
correlated with the clinical outcome, independently of
known risk factors (presence of hypertension, reduced GFR,
severity of proteinuria, blood pressure) at the time of diag-
nosis. Furthermore, the tubular atrophy/interstitial fibrosis
(T) score is the strongest predictor of kidney survival. In
2017, the Oxford classification was updated with the addi-
tion of crescent scores (C) that showed association with the
rate of GFR loss, even in treated patients with immuno-
suppression (Cheng and Barratt, 2018; Coppo et al., 2020).
The novel international IgAN prediction tool (PT) was pub-
lished in April 2019 (New International IgAN ...). PT is an
innovation in determination of IgAN prognosis because it
combines both clinical and histological parameters in one
risk-prediction tool that may provide us with accurate infor-
mation about disease progression. This PT was designed to
predict the risk of 50% decline in GFR or ESRD and can
globally be applied at the time of kidney biopsy to multiple
ethnic groups. For risk calculation, the following patient
data are required at the time of biopsy: age, race, estimated
GFR, blood pressure, proteinuria, use of medications that
block the renin–angiotensin system (angiotensin-converting
enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs)), immunosuppression use at or prior to bi-
opsy, and the Oxford MEST-C histology score (Barbour et
al., 2019), but without the C score (crescent), because the
PT authors found crescents significantly correlated with
race/ethnicity and immunosuppression after the biopsy
(Barbour et al., 2019). This study included a large group of
3927 patients from Europe, North America, China, and Ja-
pan; there were no other available studies about PT valida-
tion in other countries and regions.
Taking into consideration that there is evidence to suggest
that true variation in disease frequency may exist between
populations of different ethnicity, PT should be evaluated
before its use in the further clinical practice of nephrolo-
gists. Our study aimed to clarify PT reliability in an adult
Latvian population. PT could help to decide the best treat-
ment plan for each patient and have greater disease-
prognosis reliability in clinical practice.
MATERIALS AND METHODS
Our research was a retrospective cohort study at Pauls Stra-
diòð Clinical University Hospital Nephrology Centre
(PSCUH). Mandatory data such as age, race, estimated GFR
level, systolic (SBP) and diastolic blood pressure (DBP),
24-hour proteinuria, use of ACEI or ARB at the time of bi-
opsy, use of immunosuppression at or prior to biopsy, and
MEST scores for PT were collected. GFR was calculated by
the chronic-kidney-disease epidemiology-collaboration
(CKD-EPI) formula (eGFR using CKD-EPI…; Levey et al.,
2009). Adults who were at least 18 years old, with a mor-
phologically confirmed IgAN by the presence of IgA depos-
its by immunofluorescence microscopy from 1 January
2013 to 1 November 2019, were included in this study.
We used descriptive statistics to describe our study popula-
tion. Kidney survival was analysed with the Kaplan–Meier
method, and statistical comparison was analysed by a log-
rank test. Kidney survival was defined as having a GFR 15
ml/min /1.73 m2 within five years after the biopsy.
Definitions:
1. Predicted risk — risk of 50% decline in GFR or ESRD
calculated by the novel international IgAN prediction
tool;
2. Observed risk — risk of 50% decline in GFR or ESRD
calculated by the Cox regression model considering the
same parameters as in the PT.
To compare our data to the novel international IgAN predic-
tion tool, the following tests were performed:
1. Observed risk calculation by the Cox regression model.
2. Intraclass correlation coefficient to describe the strength
of the resemblance of PT and Cox regression.
3. We calculated differences between predicted and ob-
served risks, and the results were interpreted as follows:
• if the difference was below zero (negative), we con-
cluded that PT assigned lower risk than our observed
risk; and
• if the difference was above zero (positive), we con-
cluded that PT assigned higher risk than our ob-
served risk.
All p-values less than 0.05 were considered statistically sig-
nificant, except Hazard ratio p-values that were considered
statistically significant with smaller values (less than 0.2).
Rates of episodes per patient year were calculated in two
patient groups, with patients included in (1) Kaplan–Meier
analysis, and the Cox regression model with (2) five-year
analysis.
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In the first group, episodes were defined as GFR less than
15 ml/min/1.73 m2; in the second group, episodes were de-
fined according to PT definition, with 50% decline in GFR
or ESRD five years after the biopsy.
Histologic changes in both PT and our centre study were
scored according to Oxford IgAN classification criteria (see
Table 1) (Cheng and Barratt, 2018).
Data were analysed by R v.4.0.1 (R Core Team (2020): R:
A language and environment for statistical computing; R
Foundation for Statistical Computing, Vienna, Austria and
IBM SPSS Statistics 22.0.
The present study was approved by the PSCUH Ethics
Committee (approval no. 090919-15L; 9 September 2019).
RESULTS
Our study included 105 patients, all of them Caucasian;
90.5% (n = 95) of them were included in Kaplan–Meier
analysis, and 9.5% (n = 10) were excluded due to ESRD at
the time of biopsy. Furthermore, 68.8% (n = 68) of all pa-
tients were eligible for PT analysis, and 35.2% (n = 37) of
the patients were excluded from risk calculation by PT due
to secondary IgAN associated with liver disease or IgA vas-
culitis according to the handout for nephrologists about PT
application in clinical practice (The International IgA…);
patients with missing data were also excluded. The selected
group was analysed by the Cox regression model and PT
five years after the biopsy (see Fig. 1).
Demographic and clinical characteristics of included pa-
tients are presented in Table 2. Kaplan–Meier analysis of
kidney survival included 95 patients, 53 of them men; mean
age was 38.6 ± 11.2 years (from 18 to 72 years), and me-
dian GFR level was 56 ml/min/1.73 m2 (from 16 to 130
ml/min/1.73 m2). Nephritic syndrome was a common IgAN
manifestation. Hypertension was present in 56.4% of pa-
tients (SBP 140 mmHg or/and DBP 90 mmHg), and
39.62% of them were using ACEIs/ARBs at the time of bi-
opsy. Histologically findings were as follows: 12.6% (n =
12) of patients had M0; E0, 96.8% of patients (n = 92); S0,
27.4% (n = 26); and T0 and T1, 82.1% (n = 78), and 11.6%
(n = 11) of patients, respectively.
In this patient-population event (GFR < 15 ml/min/1.73
m2), the rate was 0.11 episodes per patient year. The me-
dian duration of the follow-up was 18.00 months (from 0 to
60 months). In this study overall median kidney survival
during the follow-up period (60 months) was not reached,
and achieved Q3 was 24 months. Gender, MEST T score,
and diastolic blood pressure were significant risk factors for
decreased kidney survival. The effect of systolic blood pres-
sure was at the border of statistical significance (p = 0.059).
Women had longer median kidney-survival time (more than
60 months) than for men (58 months). A log-rank test was
conducted to determine if there were differences in survival
distribution for gender; 2(1) = 4.03, p = 0.045 (see Fig. 2).
Analysis of kidney survival according to the MEST score
showed that patients with MEST T0 had longer median kid-
ney-survival time than the follow-up period (60 months). It
was longer than that in patients with T1 and T2, which was
40 and 18 months, respectively. There was a statistically
significant difference in kidney-survival distribution be-
tween T0 and T1 scores ( 2(2) = 9.09, p = 0.01; see Fig. 3).
As shown in Figure 3, T1 exhibited a tendency towards
better overall survival than T2 ( 2 for trends = 8.80, p =
0.003).
Participants with diastolic blood pressure (DBP) of less than
80 to 99 mmHg had longer median kidney survival than the
follow-up period (60 months), which was longer than in pa-
tients with DBP from 100 to 109 and more than 110 mmHg,
which was 40 months and 24 months. There was a statisti-
cally significant difference in survival distribution between
DBP categories ( 2(4) = 11.46, p = 0.022; see Fig. 4). Fig-
ure 4 shows the relationship between higher blood pressure
and worse kidney survival ( 2 for trend = 9.21, p = 0.002).
Table 1. Oxford classification of immunoglobulin A nephropathy (IgAN)
(Cheng and Barratt, 2018)
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Fig. 1. Overview of the patient-selection process.
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In this study, survival distribution for age, 24-hour protein-
uria, use of ACEIs/ARBs at the time of biopsy, the use of
immunosuppression at or prior to biopsy, and MEST M, E,












































































































Fig. 2. Cumulative kidney-survival rates categorised by gender.
Fig. 3. Cumulative kidney -survival rates categorised by tubular atro-
phy/interstitial fibrosis (MEST T) score.
Fig. 4. Cumulative kidney-survival rates categorised by diastolic blood
pressure.
DBP: grade 0 – < 80 mmHg; grade 1 – 80-89 mmHg; grade 2 – 90–99
mmHg; grade 3 – 100–109 mmHg; grade 4 – 110 mmHg.
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and S scores were not significantly related with kidney sur-
vival.
The study population for Cox Regression analysis Event
rate (50% decline in GFR or ESRD) was 0.15 episodes per
patient year for five-year analysis. The median follow-up
duration was 21.5 months (from 0 to 60 months) for five-
year analysis. A total of 68 patients were included for Cox
regression analysis; 37 of them were men, and the patient
mean age was 39.1 ± 12.0 years (range from 18 to 72
years). We excluded 37 patients from the study due to miss-
ing data, secondary IgAN (IgA vasculitis, liver disease), and
GFR ml/min/1.73 m2 at the time of biopsy. Glomerular
manifestations were analysed in 98.5% (n = 67) of patients
due to missing data. Table 2 lists the demographic and clini-
cal characteristics of patients.
Hazard ratio analysis showed that diastolic blood pressure,
MEST E and MEST T were associated with the risk of 50%
decline in GFR or ESRD, respectively (see Table 3). A 6%
increase in risk was observed with every next DBP grade.
There was a 4-fold increase in the risk for each MEST E
score and more than two times for each MEST T score. Age
was a protective factor, and every year the risk decreased by
5%.
The intraclass correlation coefficient showed that there was
a moderate degree of reliability between predicted and ob-
served five-year risk. The average-measure intraclass corre-
lation coefficient was 0.70 with a 95% confidence interval
from 0.52 to 0.82 (F (67,67) = 3.38, p = 0.001). The differ-
ences between predicted and observed data were mostly in-
significant from 0 to 10% (n = 33); the median difference
was 2.54%. This proves a good reliability of PT. It assigned
lower risk than our estimated risk to 23 patients, but the risk
was similar or slightly higher in 45 patients However, the
predicted maximal negative and maximal positive differ-
ences were 77.35% and 59.84%, respectively. On closer
analysis of these two study participants, no exceptional fea-
tures in their disease course or histology results were found
(see Fig. 5).
DISCUSSION
This study consisted of two parts: the first was focused on
actual kidney-survival analysis, and the second draws atten-
tion to IgAN PT validation in our study population. To our
knowledge, this is the first study that tested PT, and com-
pared predicted and observed risks of kidney-disease pro-
gression, after the PT became available online.
Routine detection of immunoglobulins including IgA in
kidney biopsies became available in Latvia from 2013, and
all patients from that moment were included in this study.
Several studies indicated that hypertension prevalence in
IgAN patients may vary between 19% and 53% at the time
of kidney biopsy (Nagy et al., 2005). In our study group,
57.3% (n = 59) of included patients had hypertension de-
fined as SBP 140 mmHg and/or DBP 90 mmHg, and
only 22 were using ACEIs/ARBs at the time of biopsy. This
can be explained by the late referral to a nephrologist in the
absence of other clinical symptoms. In this study, we found
that the blood pressure affects kidney survival; patients with
lower blood pressure had longer kidney survival. Rauen et
al. (2018) found that kidney function at the time of
histological glomerulonephritis diagnosis is associated with
clinical outcome and concluded that better prognosis may
be related to the early initiation of a specific drug treatment
(Rauen et al., 2018). However, there is currently no specific
treatment for IgAN, and the STOP-IgAN trial proved that
even immunosuppressive therapy cannot prevent GFR loss
(Rauen et al., 2018). Therefore, further research on IgAN
pathogenesis and new therapeutic targets is an ongoing
global process.
The five-year kidney survival time was 57% in our study
group, while the Japanese study of 30-year analysis of kid-
ney survival (n = 1012) showed that five-year kidney sur-
vival was more than 90% (Moriyama et al., 2014). Statis-
tically significant kidney-survival-affecting factors were
gender, MEST T score, and diastolic blood pressure. In our
study, we observed that patients with T0 had median kid-
ney-survival time that was longer than five years, and pa-
tients with T1 had a median kidney-survival time of 40
months, but patients with T2 had a shorter kidney-survival
time, 18 months. A French study that included 61 partici-
pants established that MEST T and S scores affected kidney
survival, but MEST M and E scores did not affect kidney
outcome; patients with T0 and T1 had kidney survival
greater than five years, in comparison with T2, where kid-
ney survival was only ten months. The authors of this study
concluded that MEST T scores were associated with poor
kidney outcome (Hennino et al., 2016). The VALIGA study




Age 0.95 (0.91–0.99) 0.023
Systolic blood pressure 0.99 (0.96–1.03) 0.683
Diastolic blood pressure 1.06 (1.00 –1.12) 0.04
MEST E 4.12 (0.83–20.47) 0.084
MEST T 2.52 (1.38–4.62) 0.003
Fig. 5. PT and Cox regression-model difference of estimated risks
(five-year analysis).
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and secondary analysis of the STOP-IgAN study also
showed that T scores were related with GFR loss and worse
kidney outcomes (Schimpf et al., 2018; Coppo et al., 2020).
Another retrospective study of kidney-survival analysis was
published in 2003. This study included patients from four
different countries in three continents and aimed to analyse
long-term IgAN outcomes. This study observed that 10-year
kidney survival was 95.7% in Helsinki (Finland), 87.0% in
Sydney (Australia), 63.9% in Glasgow (United Kingdom),
and 61.6% in Toronto (Canada). In addition, kidney-
survival-curve analysis showed five-year kidney survival in
98% (Helsinki), 95% (Sydney), and 79% (Glasgow and To-
ronto) of cases (Colin et al., 2003). If we compare our study
to the Japanese and tricontinental studies, we can conclude
that, in Latvia, disease courses are more aggressive, and pa-
tients reach ESRD earlier. Indications of kidney biopsy in
each country certainly play a role. In Japan, a kidney biopsy
is performed in all patients with suspected glomerulonephri-
tis; in Latvia, diagnosis verification is usually done in pa-
tients with other kidney manifestations like proteinuria, hy-
pertension, or GFR decline. Patients with isolated
haematuria are frequently not referred for biopsy.
IgAN progression may vary by geographic region. There
could be genetic influence on the course of the disease, be-
cause IgAN occurs in families and in HLA-identical sib-
lings. There is increased frequency of certain HLA and
complement genotypes in some populations, as well as ge-
netic predisposition of aberrant glycosylation, which is one
of the main components of IgAN pathogenesis (Rodrigues
et al., 2017; Kumar et al., 2018; Schena and Nistor, 2018;
Roberts, 2019). Since the Middle Ages, the territory of Lat-
via has been a frequent focal point for conquests from Ger-
many, Poland, Sweden, and Russia due to its strategic loca-
tion. The Baltic Sea was a geographical barrier to human
migration when changes in the genetic constitution due to
migration were most profound. Modern molecular genetic
investigations of the Latvian population began only 20
years ago. Review authors about Latvian population genet-
ics observed that the mitochondrial DNA of Latvians is ge-
netically similar in general with that of a majority of other
Europeans, but the Y-chromosomal lineage composition
suggests that Latvians are more similar to Northern and
Eastern European populations like Lithuanians, Estonians,
and Eastern Slavic populations due to ethnological proxim-
ity to them. Ancient DNA analysis did not observe any
genomic evidence of gene flow from Central European
farmers, or any typically mitochondrial or Y-chromosome
haplogroups for them in hunter gatherers from the territory
of today’s Latvia and Lithuania (Krûmiòa et al., 2018). Ge-
netic analysis of IgAN progression in the Latvian popula-
tion could be an important topic of further research in the
future.
Since there was no validated tool to predict IgAN progres-
sion, the PT authors derived and validated a prediction tool
for disease-progression determination. The study population
of “evaluating a new international risk-prediction tool in
IgA nephropathy” was patients from multiethnical cohorts
of adults with biopsy-proven IgAN, and it included patients
from Oxford, North American, and VALIGA studies. In
VALIGA, patients from 53 centres in 13 countries were en-
rolled, and it included only one centre from the Baltic States
(Estonia, Tartu), but many centres from Italy; this could in-
dicate that the study population was nonhomogeneous
(Barbour et al., 2019; Coppo et al., 2020). Considering that
the course of IgAN may vary in different geographical ar-
eas, and the Latvian population may differ from the general
population of Europe, it is important to clarify the disease
course in the Latvian population. Before the PT was pub-
lished, the treatment decision was based on patient clinico-
pathologic features; however, as mentioned in the PT au-
thors’ publication, clinical trials suggested that 33% of
patients who did not meet clinical-treatment criteria but had
high MEST scores did not receive treatment and experi-
enced a decrease of kidney function, and more than 75% of
patients with low-risk nonprogressive disease were unnec-
essarily treated (Barbour et al., 2019). There were some pa-
tients in our study already with ESRD at the time of biopsy,
so we agree with the authors’ opinion that the PT can poten-
tially improve clinical-treatment decisions, and it is possible
to identify high-risk patients before IgAN progresses to
ESRD.
Before we accept PT for the clinical practice of nephrolo-
gists in Latvia, we needed to verify PT reliability in our
study population. In this study, we observed that the pre-
dicted and observed risk of 50% decline in GFR or ESRD
were similar. In addition, we found that the predicted and
observed results moderately resembled each other for five-
year analysis. The results were similar, so PT is reliable for
use in Latvian population. There has been only one study
with a similar design about PT validation available until
now, besides that from the PT authors. Zhang et al. (2020)
externally validated the PT using a large cohort of 1373 pa-
tients with biopsy-proven primary IgAN from central
China. The authors validated PT to predict five-year risk of
kidney outcomes; however, the median follow-up of their
cohort was 29 months. They concluded that PT can be ap-
plied in clinical practise for individual patients at an early
disease stage and further multicentre studies are required to
change clinical decisions (Zhang et al., 2020).
In both humans and laboratory animals, the specific causes
underlying the sex differences in kidney disease progression
are unclear but have been speculated to involve factors such
as innate sex-related variability in kidney size, weight, and
nephron number, gender differences in systemic and glom-
erular haemodynamics, differences in diet, and the direct ef-
fects of estrogens and androgens on kidney tissue (Silbiger,
2011). Gender affected kidney survival, with women having
longer kidney survival than men, and there were differences
between predicted and observed data; for females, predicted
and observed risks were more similar compared with those
for males. Meta-analysis of randomised controlled trials
about ACEI/ARB agent effects on IgAN showed that, in
comparison with the control groups, ACEIs/ARBs agents
had statistically significant effects on protecting kidney
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function (Cheng et al., 2009). MEST scores are important
factors that influence IgAN prognosis. More precisely, it
was found that mesangial hypercellularity (M) and tubular
atrophy/ interstitial fibrosis (T) were associated with poor
kidney outcome (Barbour et al., 2016; Chen et al., 2018).
We found that tubular atrophy/interstitial fibrosis (T) had
statistically significant impact on kidney survival, and me-
sangial hypercellularity (M) did not have a statistically sig-
nificant effect on kidney survival, but it affected differences
between PT and estimated risk.
Our study had some limitations. The main limitation was
the relatively small study cohort, and insufficient data about
kidney function and disease course after five years (for ex-
ample, for patients who had a kidney biopsy in 2018). This
was a retrospective design study. Some of the patients were
excluded from the study due to missing information in
medical records or secondary IgAN. Patients receiving im-
munosuppressive therapy and its effects were not separately
analysed. This study needs to be performed in a larger co-
hort with a longer follow-up period (ten years, for example)
for more accurate data analysis. This would allow for more
precise data comparison with those of other studies. This is
possible after the creation of a single database for the Baltic
region.
CONCLUSIONS
Episodes per patient years were less than 0.20 in both
Kaplan–Meier analysis, and the five-year Cox regres-
sion-model group. More than a half of the study population
had longer kidney survival than five years. Kidney-sur-
vival-affecting factors were gender, tubular atrophy/intersti-
tial fibrosis (MEST T), and diastolic blood pressure. Not-
withstanding ethnic and demographic differences between
our cohort and the population in the PT study, predicted and
observed risk of 50% decline in GFR or ESRD were simi-
lar. Therefore, this tool can be applied to IgAN patients in
the Latvian population.
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NIERU DZÎVILDZE UN JAUNÂ STARPTAUTISKÂ IMÛNGLOBULÎNA A NEFROPÂTIJAS PROGNOZES KALKULATORA
VALIDÂCIJA LATVIJAS POPULÂCIJÂ: PRELIMINÂRIE DATI
Imûnglobulîna A nefropâtija (IgAN) ir bieþâkais glomerulonefrîta veids visâ pasaulç, taèu slimîbas ìeogrâfiskâ izplatîba un klîniskâs
pazîmes ievçrojami atðíiras. Retrospektîva kohortas pçtîjuma mçríis bija noteikt nieru piecu gadu dzîvildzi, izmantojot Kaplana–Meiera
metodi) un validçt starptautisko IgAN prognozes kalkulatoru (PK), izmantojot Koksa regresijas analîzi Latvijas populâcijâ. Pçtîjums tika
veikts Paula Stradiòa Klîniskâs universitâtes slimnîcas Nefroloìijas centrâ un tajâ tika iekïauti vismaz 18 gadus veci pacienti ar histoloìiski
apstiprinâtu IgAN diagnozi. Kaplana–Meiera analîzç tika iekïauti 95 pacienti, un nieru piecu gadu dzîvildzes Q3 bija 24 mçneði. Nieru
dzîvildzes mediâna sievietçm bija ilgâka (> 60 mçneði) nekâ vîrieðiem (58 mçneði), p = 0,045. Pacientiem ar MEST T0 nieru dzîvildzes
mediâna bija > 60 mçneði, T1 un T2 tâ bija, attiecîgi, 40 un 18 mçneði. Pacientiem ar diastolisko asinsspiedienu (DAS) > 99 mmHg
mediânâ nieru dzîvildze bija > 60 mçneði, savukârt, pacientiem ar DAS 100–109 un 110 mmHg tâ bija attiecîgi 40 un 24 mçneði. Koksa
regresijas analîzç tika iekïauti 68 pacienti, un tika novçrota mçrena ticamîba starp aprçíinâtu risku ar PK un Koksa regresiju. Rezultâti
liecina, ka starptautisko IgAN prognozes kalkulatoru varçtu izmantot nefrologu klîniskajâ praksç Latvijâ.
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